The success achieved with EGFR tyrosine kinase inhibitors (EGFR-TKIs) in advanced NSCLC patients has promoted the investigation of EGFR-TKIs as adjuvant treatment for resected EGFR-mutant NSCLC patients [4, 5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.